Adenocarcinoma
Welcome,         Profile    Billing    Logout  
 312 Companies   432 Products   432 Products   193 Mechanisms of Action   36 Trials   6238 News 


«12...345678910111213...124125»
  • ||||||||||  Trial completion:  ADK-FO: Mechanisms of Cancerogenesis of Woodworkers Adenocarcinomas (clinicaltrials.gov) -  Feb 6, 2018   
    P=N/A,  N=28, Completed, 
    Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 | Initiation date: Mar 2012 --> Mar 2012 Recruiting --> Completed
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion, Combination therapy:  S-1 in Combination With Abraxane in Treating Cholangiocarcinoma (clinicaltrials.gov) -  Feb 5, 2018   
    P2,  N=50, Completed, 
    Recruiting --> Active, not recruiting Terminated --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  Follow up After Cryoablation of Small Renal Masses. (clinicaltrials.gov) -  Feb 5, 2018   
    P=N/A,  N=12, Recruiting, 
    Terminated --> Completed Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date:  Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer (clinicaltrials.gov) -  Feb 1, 2018   
    P1,  N=0, Withdrawn, 
    Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 N=24 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Sep 2014 --> Feb 2016
  • ||||||||||  gemcitabine / Generic mfg., tadalafil / Generic mfg.
    Trial completion, Metastases:  Chemoimmunotherapy and Radiation in Pancreatic Cancer (clinicaltrials.gov) -  Feb 1, 2018   
    P1,  N=10, Completed, 
    N=24 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Sep 2014 --> Feb 2016 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Prostate Conformal Cryotherapy (clinicaltrials.gov) -  Jan 31, 2018   
    P=N/A,  N=48, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 48 | Trial primary completion date: Apr 2019 --> Jan 2018
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Phase classification, Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Jan 31, 2018   
    P2,  N=51, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jan 2010; PI left UNMC Phase classification: P1 --> P2
  • ||||||||||  GI-6301 / BMS
    Trial completion, Trial primary completion date:  Cancer Vaccine Targeting Brachyury Protein in Tumors (clinicaltrials.gov) -  Jan 29, 2018   
    P1,  N=34, Completed, 
    Recruiting --> Completed | N=24 --> 17 | Trial primary completion date: Dec 2018 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016
  • ||||||||||  Phase classification, Enrollment change, Trial termination, Trial primary completion date:  Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures (clinicaltrials.gov) -  Jan 26, 2018   
    P=N/A,  N=42, Terminated, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016 Phase classification: P2/3 --> P=N/A | N=116 --> 42 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Dec 2017; Poor recruitment
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Trial primary completion date, Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Jan 25, 2018   
    P1,  N=51, Active, not recruiting, 
    Phase classification: P2/3 --> P=N/A | N=116 --> 42 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Dec 2017; Poor recruitment Trial primary completion date: Jan 2019 --> Apr 2018
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Perfusion Scanning's for Kidney Tumors (clinicaltrials.gov) -  Jan 24, 2018   
    P=N/A,  N=56, Completed, 
    Trial primary completion date: Dec 2020 --> Jul 2016 Recruiting --> Completed | N=100 --> 56 | Trial primary completion date: Dec 2018 --> Jan 2018
  • ||||||||||  carotuximab IV (ENV105) / Kairos Pharma
    Trial completion, Combination therapy, IO biomarker:  Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) -  Jan 23, 2018   
    P1/2,  N=27, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  TheraSphere (yttrium 90 microspheres) / Boston Scientific
    Trial completion, Trial primary completion date:  MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) -  Jan 19, 2018   
    P2,  N=41, Completed, 
    N=20 --> 14 | Active, not recruiting --> Terminated; The sponsor's clinical program for the agent used in this study was discontinued. Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2016
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 17, 2018   
    P1,  N=96, Completed, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
  • ||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
    Trial primary completion date, Metastases:  Gastric Cancer RAD001 Study (clinicaltrials.gov) -  Jan 17, 2018   
    P1/2,  N=35, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Phase classification, Enrollment change, Trial termination, Trial primary completion date:  CINE-Cyst: Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions (clinicaltrials.gov) -  Jan 17, 2018   
    P=N/A,  N=10, Terminated, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P1 --> P=N/A | N=200 --> 10 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  prednisone / Generic mfg., everolimus / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI (clinicaltrials.gov) -  Jan 16, 2018   
    P2,  N=8, Terminated, 
    Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2017 N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2017
  • ||||||||||  Gilotrif (afatinib) / Boehringer Ingelheim
    Trial primary completion date:  The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting (clinicaltrials.gov) -  Jan 12, 2018   
    P2,  N=2, Terminated, 
    Trial primary completion date: Sep 2017 --> Apr 2018 Trial primary completion date: Jul 2019 --> Aug 2017
  • ||||||||||  docetaxel / Generic mfg.
    Trial completion, Metastases:  Docetaxel and Lycopene in Metastatic Prostate Cancer (clinicaltrials.gov) -  Jan 11, 2018   
    P1,  N=24, Completed, 
    Trial primary completion date: Jul 2019 --> Aug 2017 Active, not recruiting --> Completed
  • ||||||||||  Tookad (padeliporfin) / Steba Biotech
    Enrollment change:  Vascular Targeted Photodynamic Therapy T1a Renal Tumours (clinicaltrials.gov) -  Jan 10, 2018   
    P2a,  N=5, Terminated, 
    Active, not recruiting --> Completed N=12 --> 5
  • ||||||||||  sorafenib / Generic mfg.
    Enrollment change, Trial withdrawal:  Randomized Phase II Trial of Chemoembolization and Sorafenib (clinicaltrials.gov) -  Jan 10, 2018   
    P2,  N=0, Withdrawn, 
    Recruiting --> Completed | N=25 --> 32 N=64 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  PF-04136309 / Pfizer
    Trial termination, Combination therapy, Metastases:  Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) -  Jan 9, 2018   
    P1b/2,  N=21, Terminated, 
    Trial primary completion date: Jun 2017 --> Dec 2017 Completed --> Terminated; Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Trial primary completion date:  Study To Assess Long Term Safety Of Pazopanib (clinicaltrials.gov) -  Jan 8, 2018   
    P1,  N=195, Active, not recruiting, 
    Completed --> Terminated; Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy. Trial primary completion date: Dec 2017 --> Mar 2018
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Trial primary completion date, Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Jan 5, 2018   
    P1,  N=51, Active, not recruiting, 
    Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Jan 2018 --> Jan 2019